Guardant Health (GH) director converts 232 RSUs into common shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Guardant Health director Manuel Hidalgo Medina reported acquiring shares through equity awards. On the vesting of a restricted stock unit grant on July 17, 2024, 232 restricted stock units converted into 232 shares of common stock at a price of $0.00 per share, reflecting an exercise or conversion of a derivative security rather than an open-market purchase. After these transactions, he directly holds 6,729 restricted stock units and 1,493 shares of common stock. The award vests over four years, with 25% vesting on the one-year anniversary of July 17, 2024 and the remaining 75% vesting monthly over the following three years.

Insider Trade Summary

232 shares exercised/converted

Mixed 2 txns

Insider Hidalgo Medina Manuel

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	232	$0.00	--
Exercise	Common Stock	232	$0.00	--

Holdings After Transaction: Restricted Stock Units — 6,729 shares (Direct); Common Stock — 1,493 shares (Direct)

Footnotes (1)

The restricted stock unit award granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of July 17, 2024 and the remaining 75% vests monthly for the three-year period thereafter. Not applicable for Restricted Stock Units.

Form 4 Insider Transactions: What Each Field Means →

02/18/2026 - 04:27 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hidalgo Medina Manuel

(Last)

(First)

(Middle)

3100 HANOVER STREET

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/17/2026		M		232	A	$0	1,493	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	02/17/2026		M			232	⁽¹⁾	⁽²⁾	Common Stock	232	$0	6,729	D

Explanation of Responses:

1. The restricted stock unit award granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of July 17, 2024 and the remaining 75% vests monthly for the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Manuel Hidalgo Medina	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Guardant Health (GH) director Manuel Hidalgo Medina report on this Form 4?

He reported an equity award vesting that converted 232 restricted stock units into 232 shares of Guardant Health common stock. This was recorded as an exercise or conversion of a derivative security at no cash cost per share.

How many Guardant Health shares did Manuel Hidalgo Medina acquire in this transaction?

He acquired 232 shares of Guardant Health common stock upon the conversion of 232 restricted stock units. The transaction was coded as an exercise or conversion of a derivative security, with a reported price of $0.00 per share.

What is the vesting schedule of Manuel Hidalgo Medina’s Guardant Health restricted stock units?

The restricted stock unit award granted on July 17, 2024 vests over four years. Twenty-five percent vested on the one-year anniversary of that date, and the remaining 75% vests monthly over the following three-year period.

How many Guardant Health restricted stock units does Manuel Hidalgo Medina hold after this filing?

Following the reported transaction, he holds 6,729 restricted stock units of Guardant Health. These units continue to vest over time according to the four-year vesting schedule disclosed for the July 17, 2024 award.

How many Guardant Health common shares does Manuel Hidalgo Medina own after the conversion?

After the conversion of restricted stock units, he directly owns 1,493 shares of Guardant Health common stock. These holdings are separate from his remaining restricted stock units, which will convert into additional shares as they vest.

Was this Guardant Health Form 4 a market purchase or sale of shares?

No, the filing shows an exercise or conversion of a derivative security. Restricted stock units vested and converted into common shares at $0.00 per share, rather than an open-market buy or sell transaction.